248 related articles for article (PubMed ID: 18496242)
1. The response of antithrombin III activity after supplementation decreases in proportion to the severity of sepsis and liver dysfunction.
Hayakawa M; Sawamura A; Yanagida Y; Sugano M; Hoshino H; Gando S
Shock; 2008 Dec; 30(6):649-52. PubMed ID: 18496242
[TBL] [Abstract][Full Text] [Related]
2. [[Antithrombin III concentrates in the treatmetn of sepsis and septic shock: indictions, limits and future prospects] ].
Baudo F; de Cataldo F
Minerva Anestesiol; 2000 Nov; 66(11 Suppl 1):3-23. PubMed ID: 11213542
[TBL] [Abstract][Full Text] [Related]
3. Activity-guided antithrombin III therapy in severe surgical sepsis: efficacy and safety according to a retrospective data analysis.
Moubarak P; Zilker S; Wolf H; Hofner B; Kneib T; Küchenhoff H; Jauch KW; Hartl WH
Shock; 2008 Dec; 30(6):634-41. PubMed ID: 18520701
[TBL] [Abstract][Full Text] [Related]
4. Antithrombin supplementation for anticoagulation during continuous hemofiltration in critically ill patients with septic shock: a case-control study.
du Cheyron D; Bouchet B; Bruel C; Daubin C; Ramakers M; Charbonneau P
Crit Care; 2006; 10(2):R45. PubMed ID: 16542495
[TBL] [Abstract][Full Text] [Related]
5. First day dynamic changes in antithrombin III activity after supplementation have a predictive value in critically ill patients.
Gando S; Sawamura A; Hayakawa M; Hoshino H; Kubota N; Oshiro A
Am J Hematol; 2006 Dec; 81(12):907-14. PubMed ID: 16924643
[TBL] [Abstract][Full Text] [Related]
6. Use of protein C concentrate in pediatric patients with sepsis.
Silvani P; Camporesi A; Licari E; Wolfler A
Minerva Anestesiol; 2005 Jun; 71(6):373-8. PubMed ID: 15886604
[TBL] [Abstract][Full Text] [Related]
7. The effect of anticoagulants and the role of thrombin on neutrophil-endothelial cell interactions in septic shock.
Tsen A; Kirschenbaum LA; LaRow C; Khan R; Kurtz S; Bansal S; Astiz ME
Shock; 2009 Feb; 31(2):120-4. PubMed ID: 18636042
[TBL] [Abstract][Full Text] [Related]
8. [Are there certified indications for the use of antithrombin III in intensive care].
Kulka PJ; Tryba M; Lange S
Anasthesiol Intensivmed Notfallmed Schmerzther; 2001 Mar; 36(3):143-53. PubMed ID: 11324345
[TBL] [Abstract][Full Text] [Related]
9. [Antithrombin III in severe sepsis and septic shock].
Carrillo-Esper R; Núñez-Monroy FN
Gac Med Mex; 1999; 135(4):443-6. PubMed ID: 10491905
[No Abstract] [Full Text] [Related]
10. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial.
Warren BL; Eid A; Singer P; Pillay SS; Carl P; Novak I; Chalupa P; Atherstone A; Pénzes I; Kübler A; Knaub S; Keinecke HO; Heinrichs H; Schindel F; Juers M; Bone RC; Opal SM;
JAMA; 2001 Oct; 286(15):1869-78. PubMed ID: 11597289
[TBL] [Abstract][Full Text] [Related]
11. [Antithrombin therapy of no value in sepsis according to a large clinical trial].
Gårdlund B
Lakartidningen; 2002 Mar; 99(13):1456-7, 1460. PubMed ID: 11989356
[TBL] [Abstract][Full Text] [Related]
12. Antithrombin-III treatment limits disseminated intravascular coagulation in endotoxemia.
Redens TB; Emerson TE
Circ Shock; 1989 May; 28(1):49-58. PubMed ID: 2731321
[TBL] [Abstract][Full Text] [Related]
13. The vasopressin and copeptin response to infection, severe sepsis, and septic shock.
Jochberger S; Dörler J; Luckner G; Mayr VD; Wenzel V; Ulmer H; Morgenthaler NG; Hasibeder WR; Dünser MW
Crit Care Med; 2009 Feb; 37(2):476-82. PubMed ID: 19114902
[TBL] [Abstract][Full Text] [Related]
14. A meta-analysis of controlled trials of anticoagulant therapies in patients with sepsis.
Freeman BD; Zehnbauer BA; Buchman TG
Shock; 2003 Jul; 20(1):5-9. PubMed ID: 12813361
[TBL] [Abstract][Full Text] [Related]
15. Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis.
Inthorn D; Hoffmann JN; Hartl WH; Mühlbayer D; Jochum M
Shock; 1998 Aug; 10(2):90-6. PubMed ID: 9721974
[TBL] [Abstract][Full Text] [Related]
16. Acquired antithrombin deficiency following severe traumatic injury: rationale for study of antithrombin supplementation.
Owings JT; Gosselin R
Semin Thromb Hemost; 1997; 23 Suppl 1():17-24. PubMed ID: 9156418
[TBL] [Abstract][Full Text] [Related]
17. Antithrombin III supplementation reduces heparin requirement and platelet loss during hemodialysis of patients with fulminant hepatic failure.
Langley PG; Keays R; Hughes RD; Forbes A; Delvos U; Williams R
Hepatology; 1991 Aug; 14(2):251-6. PubMed ID: 1860682
[TBL] [Abstract][Full Text] [Related]
18. Early intervention with antithrombin III therapy to prevent progression of hepatic venoocclusive disease.
Peres E; Kintzel P; Dansey R; Baynes R; Abidi M; Klein J; Ibrahim RB; Abella E
Blood Coagul Fibrinolysis; 2008 Apr; 19(3):203-7. PubMed ID: 18388499
[TBL] [Abstract][Full Text] [Related]
19. Antithrombin III in animal models of sepsis and organ failure.
Dickneite G
Semin Thromb Hemost; 1998; 24(1):61-9. PubMed ID: 9515781
[TBL] [Abstract][Full Text] [Related]
20. Antithrombin III concentrate in the treatment of DIC: a retrospective follow-up study.
van Beek EJ; von der Möhlen MA; ten Cate JW; Brandjes DP; Büller HR
Neth J Med; 1994 Nov; 45(5):206-10. PubMed ID: 7830846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
